Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

In vivo (1) H MR spectroscopic imaging of aggressive prostate cancer: can we detect lactate?

Kobus T, Wright AJ, Van Asten JJ, Heerschap A, Scheenen TW.

Magn Reson Med. 2014 Jan;71(1):26-34. doi: 10.1002/mrm.24635. Epub 2013 Mar 8.

PMID:
23475759
2.

TE = 32 ms vs TE = 100 ms echo-time (1)H-magnetic resonance spectroscopy in prostate cancer: Tumor metabolite depiction and absolute concentrations in tumors and adjacent tissues.

Basharat M, Payne GS, Morgan VA, Parker C, Dearnaley D, deSouza NM.

J Magn Reson Imaging. 2015 Oct;42(4):1086-93. doi: 10.1002/jmri.24875. Epub 2015 Aug 10.

3.

Optimal timing for in vivo 1H-MR spectroscopic imaging of the human prostate at 3T.

Scheenen TW, Gambarota G, Weiland E, Klomp DW, Fütterer JJ, Barentsz JO, Heerschap A.

Magn Reson Med. 2005 Jun;53(6):1268-74.

4.

Metabolite ratios in 1H MR spectroscopic imaging of the prostate.

Kobus T, Wright AJ, Weiland E, Heerschap A, Scheenen TW.

Magn Reson Med. 2015 Jan;73(1):1-12. doi: 10.1002/mrm.25122. Epub 2014 Jan 31. Review.

PMID:
24488656
5.

Detection of prostate cancer with MR spectroscopic imaging: an expanded paradigm incorporating polyamines.

Shukla-Dave A, Hricak H, Moskowitz C, Ishill N, Akin O, Kuroiwa K, Spector J, Kumar M, Reuter VE, Koutcher JA, Zakian KL.

Radiology. 2007 Nov;245(2):499-506. Epub 2007 Sep 21.

PMID:
17890357
6.

Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla.

McLean MA, Barrett T, Gnanapragasam VJ, Priest AN, Joubert I, Lomas DJ, Neal DE, Griffiths JR, Sala E.

Magn Reson Med. 2011 Apr;65(4):914-9. doi: 10.1002/mrm.22703. Epub 2010 Nov 16.

7.

Combined use of diffusion-weighted MRI and 1H MR spectroscopy to increase accuracy in prostate cancer detection.

Reinsberg SA, Payne GS, Riches SF, Ashley S, Brewster JM, Morgan VA, deSouza NM.

AJR Am J Roentgenol. 2007 Jan;188(1):91-8.

PMID:
17179350
8.

Hyperpolarized 13C lactate, pyruvate, and alanine: noninvasive biomarkers for prostate cancer detection and grading.

Albers MJ, Bok R, Chen AP, Cunningham CH, Zierhut ML, Zhang VY, Kohler SJ, Tropp J, Hurd RE, Yen YF, Nelson SJ, Vigneron DB, Kurhanewicz J.

Cancer Res. 2008 Oct 15;68(20):8607-15. doi: 10.1158/0008-5472.CAN-08-0749.

9.

Contribution of Histopathologic Tissue Composition to Quantitative MR Spectroscopy and Diffusion-weighted Imaging of the Prostate.

Kobus T, van der Laak JA, Maas MC, Hambrock T, Bruggink CC, Hulsbergen-van de Kaa CA, Scheenen TW, Heerschap A.

Radiology. 2016 Mar;278(3):801-11. doi: 10.1148/radiol.2015142889. Epub 2015 Sep 29.

PMID:
26418614
10.

Simple baseline correction for 1H MRSI data of the prostate.

Wright AJ, Heerschap A.

Magn Reson Med. 2012 Dec;68(6):1724-30. doi: 10.1002/mrm.24182. Epub 2012 Jan 31.

PMID:
22294517
11.

Spatially matched in vivo and ex vivo MR metabolic profiles of prostate cancer -- investigation of a correlation with Gleason score.

Selnaes KM, Gribbestad IS, Bertilsson H, Wright A, Angelsen A, Heerschap A, Tessem MB.

NMR Biomed. 2013 May;26(5):600-6. doi: 10.1002/nbm.2901. Epub 2012 Dec 27.

PMID:
23280546
12.

Prostate cancer aggressiveness: in vivo assessment of MR spectroscopy and diffusion-weighted imaging at 3 T.

Kobus T, Vos PC, Hambrock T, De Rooij M, Hulsbergen-Van de Kaa CA, Barentsz JO, Heerschap A, Scheenen TW.

Radiology. 2012 Nov;265(2):457-67. doi: 10.1148/radiol.12111744. Epub 2012 Jul 27.

PMID:
22843767
13.

Lactate MRSI and DCE MRI as surrogate markers of prostate tumor aggressiveness.

Yaligar J, Thakur SB, Bokacheva L, Carlin S, Thaler HT, Rizwan A, Lupu ME, Wang Y, Matei CC, Zakian KL, Koutcher JA.

NMR Biomed. 2012 Jan;25(1):113-22. doi: 10.1002/nbm.1723. Epub 2011 May 25.

14.

Combined morphological, [1H]-MR spectroscopic and contrast-enhanced imaging of human prostate cancer with a 3-Tesla scanner: preliminary experience.

Carlani M, Mancino S, Bonanno E, Finazzi Agrò E, Simonetti G.

Radiol Med. 2008 Aug;113(5):670-88. doi: 10.1007/s11547-008-0271-8. Epub 2008 May 20. English, Italian.

PMID:
18493829
15.

Evaluation of lactate and alanine as metabolic biomarkers of prostate cancer using 1H HR-MAS spectroscopy of biopsy tissues.

Tessem MB, Swanson MG, Keshari KR, Albers MJ, Joun D, Tabatabai ZL, Simko JP, Shinohara K, Nelson SJ, Vigneron DB, Gribbestad IS, Kurhanewicz J.

Magn Reson Med. 2008 Sep;60(3):510-6. doi: 10.1002/mrm.21694.

16.

Detection of fully refocused polyamine spins in prostate cancer at 7 T.

Klomp DW, Scheenen TW, Arteaga CS, van Asten J, Boer VO, Luijten PR.

NMR Biomed. 2011 Apr;24(3):299-306. doi: 10.1002/nbm.1592. Epub 2010 Oct 6.

PMID:
20925128
17.

Short echo time in vivo prostate ¹H-MRSI.

Venugopal N, McCurdy B, Al Mehairi S, Alamri A, Sandhu GS, Sivalingam S, Drachenberg D, Ryner L.

Magn Reson Imaging. 2012 Feb;30(2):195-204. doi: 10.1016/j.mri.2011.09.020. Epub 2011 Dec 9.

PMID:
22154684
18.

A phase and frequency alignment protocol for 1H MRSI data of the prostate.

Wright AJ, Buydens LM, Heerschap A.

NMR Biomed. 2012 May;25(5):755-65. doi: 10.1002/nbm.1790. Epub 2011 Sep 26.

PMID:
21953616
19.

Repeatability of edited lactate and other metabolites in astrocytoma at 3T.

McLean MA, Sun A, Bradstreet TE, Schaeffer AK, Liu H, Iannone R, Herman G, Railkar RA, Joubert I, Gillard JH, Price SJ, Griffiths JR.

J Magn Reson Imaging. 2012 Aug;36(2):468-75. doi: 10.1002/jmri.23673. Epub 2012 Apr 25.

PMID:
22535478
20.

Implementation of 3 T lactate-edited 3D 1H MR spectroscopic imaging with flyback echo-planar readout for gliomas patients.

Park I, Chen AP, Zierhut ML, Ozturk-Isik E, Vigneron DB, Nelson SJ.

Ann Biomed Eng. 2011 Jan;39(1):193-204. doi: 10.1007/s10439-010-0128-x. Epub 2010 Jul 23.

Supplemental Content

Support Center